BetaSense
Private Company
Total funding raised: $17.5M
Overview
BetaSense is an early-stage diagnostics company developing a proprietary structural biomarker detection platform called iRS. The technology uses infrared spectroscopy to identify misfolded proteins in biofluids like serum and CSF, demonstrating high diagnostic accuracy (AUC >0.93) for Parkinson's disease. Founded in 2025, the company operates as a CRO lab, collaborates with pharmaceutical partners, and is positioning its platform for clinical diagnostics and drug development support. Its goal is to shift neurodegenerative disease management to pre-symptomatic stages.
Technology Platform
iRS (immuno-infrared-sensor) platform: An antibody-capture coupled infrared spectroscopy system for label-free detection of disease-specific protein misfolding in biofluids.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
BetaSense competes in a crowded field of companies developing fluid biomarkers for neurodegeneration, using technologies like SIMOA, mass spectrometry, and other immunoassays. Its differentiation lies in its direct detection of protein structure (misfolding) via infrared spectroscopy, rather than just concentration.